Değer20202021202220232024TTMSatış/genel/idari giderler747 M818 M828 M926 M1.1 B—Araştırma ve geliştirme226 M230 M236 M274 M320 M—Faaliyet karı332 M389 M695 M813 M842 M—Faaliyet Dışı Gelir, Toplam——————Faiz gideri (aktifleştirilmiş faizler düşüldükten sonra)——————Faaliyet Dışı Gelir (Faiz Giderleri Hariç)——————Olağandışı gelirler/giderler——————Vergi öncesi kar361 M426 M734 M862 M900 M—Kazançlardaki özsermayeler——————Vergiler125 M115 M186 M194 M229 M—Kontrol gücü olmayan/azınlık payı————8 M—Vergi sonrası diğer gelirler/giderler——————Durdurulan faaliyetler öncesi net kar236 M311 M548 M668 M671 M—Durdurulan faaliyetler——————Net kar236 M311 M548 M668 M671 M—Seyreltme ayarlaması——————İmtiyazlı temettüler——————Adi hisse senedi sahiplerine düşen seyreltilmiş net kar——————Temel hisse başına kazanç (Temel EPS)——————Seyreltilmiş hisse başına kazanç (Seyreltilmiş EPS)——————Dolaşımdaki ortalama adi hisse senedi sayısı——————Dolaşımdaki seyreltilmiş hisse senedi sayısı——————FAVÖK——————FVÖK1.52 B1.71 B1.99 B2.2 B2.42 B—Gelir maliyeti1.19 B1.32 B1.3 B1.39 B1.58 B—Satılan malların diğer maliyeti——————Amortisman ve itfa (nakit akışı)——————
Dr. Reddy's Laboratories Ltd
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr.